In photodynamic therapy, a photosensitizing dye restrictively localized to certain sites in the biological milieu, is activated by visible light to selectively destroy the stained structures. Although primarily investigated for necroting malignant tumors, this approach suggests also potential in treating other pathological conditions such as age‐related macular degeneration and atherosclerosis. Until recently, hematoporphyring derivative was practically the only dye investigated for photodynamic therapy. The use of phthalocyanine dyes is being explored as a superior alternative photosensitizer for treatment of these diseases.
No takes yet. Share an insight, caveat, or question.
Ben‐Hur et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: